It was a tough year, that needs no emphasizing, except to say we extend our heartfelt sympathies to anyone who lost a loved one from COVID-19 this year, or from any number of other dangers that tangled up to make 2020 one of the most challenging years on record. At Cronicle Press Tech News, we were just kicking off our first full year of reporting on tech and startup news from Michigan and Midwest tech industries, and the uncertainty for us as a fledgling blog and for the companies we were reporting on was unprecedented.
During lockdown, Asalyxa Bio’s chief scientific officer Lola Eniola-Adefeso was one of the only people still working in Ann Arbor, where most work and scientific research was shut down to protect against the spread of COVID-19. Eniola-Adefeso was still working because she was one of a few scientists working on a treatment that could benefit the sickest COVID-19 patients, the ones who suffer from Acute Repiratory Distress Syndrome and cytokine storm. Eniola-Adefeso’s employer, new Ann Arbor biotech startup Asalyxa Bio, recently announced seed funding for its neutrophil targeting drug delivery technology to advance to first in-human trials next year. The tech can be used to target certain cells to treat Acute Repiratory Distress Syndrome, including the variety found in COVID-19 patients.